Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG ...

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-line treatment for CLL and small lymphocytic ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products ...

China NMPA approves InnoCare Pharma’s orelabrutinib for first-line treatment of patients with CLL/SLL: Beijing Monday, April 28, 2025, 12:00 Hrs [IST] InnoCare Pharma, a leading ...

March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that the first patient has been dosed in ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma. The EMA’s ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies ... Mucosa-associated lymphoid tissue; MCL: Mantle cell lymphoma; MTD: Maximum tolerated dose; MZL: Marginal zone lymphoma ...